SLS Plunges 13.6%: Legal Storms and Dilution Fears Trigger Violent Selloff

Summary
• SELLAS Life Sciences (SLS) shares crater 13.64% intraday, settling near $11.65 after opening at $13.55.
• Pomerantz Law Firm initiates securities fraud probe into delayed Phase 3 REGAL trial results and alleged mismanagement.
• Retail investors revolt against a proposed 20 million share issuance, citing severe dilution risks ahead of critical data.
• Stock trades between a high of $13.73 and a low of $11.38, with turnover exceeding 12.3 million shares.

A perfect storm of legal uncertainty and capital structure anxiety has battered SELLAS Life Sciences. The market is reacting violently to fears that management has obscured the release of pivotal Phase 3 data, compounded by shareholder anger over potential equity dilution. This confluence of negative sentiment has overwhelmed any prior bullish momentum, leaving traders scrambling to re-evaluate risk exposure.
Legal Probes and Dilution Fears Hammer Sellas Stock
The precipitous decline in SLS is directly attributable to two converging crises. First, Pomerantz LLP has launched an investigation into whether Sellas engaged in securities fraud by delaying the release of Phase 3 REGAL trial results after the 80th patient death event was triggered. Second, a proposed issuance of 20 million new shares has sparked outrage among retail investors who view this as a dilutive maneuver ahead of a key clinical readout. These factors have created a hostile trading environment where sellers are dominating, driven by doubts over management transparency and the immediate threat to existing equity value.

Defensive Positioning: Technical Breakdown and High-Leverage Put Strategies
The technical landscape for SLS has deteriorated sharply, confirming a short-term bearish trend despite a long-term bullish backdrop. Traders must navigate a market where support levels are being tested aggressively.

• 200-day Moving Average: $6.99 (bullish long-term baseline)
• 30-day Moving Average: $12.90 (resistance zone)
• RSI: 50.47 (neutral momentum)
• MACD Histogram: -0.096 (bearish divergence)
• Bollinger Lower Band: $12.22 (dynamic support)

The stock has broken below the 30-day moving average and the lower Bollinger Band, signaling a loss of short-term control. The MACD histogram turning negative confirms bearish momentum. With the 30-day support level at $11.75–$11.86 breached, the path of least resistance is lower. For options traders seeking exposure to this volatility, we identify two high-potential contracts from the chain that balance leverage, liquidity, and time decay characteristics.

• SLS20260918P11.5 (Put): Strike $11.50, Expiration 2026-09-18. IV: 134.08%, Leverage: 13.86%, Delta: -0.43, Theta: -0.02, Gamma: 0.17, Turnover: $57,651.
Implied Volatility: High option pricing reflecting uncertainty.
Leverage Ratio: Amplified returns relative to stock movement.
Delta: Moderate sensitivity to price drops.
Theta: Moderate time decay cost.
Gamma: High sensitivity to price changes.
Turnover: Good liquidity for entry/exit.
This contract stands out for its high gamma (0.17), making it highly responsive to intraday swings, while offering a balanced delta for directional exposure. The turnover ensures ease of execution.

• SLS20260918P12 (Put): Strike $12.00, Expiration 2026-09-18. IV: 122.77%, Leverage: 11.19%, Delta: -0.53, Theta: -0.008, Gamma: 0.19, Turnover: $65,599.
Implied Volatility: Elevated pricing for risk.
Leverage Ratio: Significant return multiplier.
Delta: High sensitivity to price drops.
Theta: Low time decay cost.
Gamma: Very high sensitivity to price changes.
Turnover: Highest liquidity in the chain.
This put option offers the highest liquidity and gamma (0.19), ideal for short-term traders betting on continued downside. The low theta (-0.008) reduces time decay pressure, making it suitable for quick trades.

Payoff Calculation Primer: Assuming a 5% downside scenario from the current price of $11.65 (projected price ~$11.07), the SLS20260918P11.5 put would yield a payoff of max(0, 11.50 - 11.07) = $0.43 per share, while the SLS20260918P12 put would yield max(0, 12.00 - 11.07) = $0.93 per share. These projections highlight the asymmetric upside of puts in a falling market.

Aggressive bears may consider SLS20260918P12 for maximum liquidity and gamma exposure if the $11.00 level breaks further.

Avoid the Fall: Stay Sideline Until Legal Clarity Emerges
The current selloff in SLS is driven by fundamental legal and structural fears rather than sector-wide weakness, making it unlikely to stabilize without clear regulatory or corporate communication. Investors should exercise extreme caution, as the combination of a securities fraud probe and dilution threats creates a volatile and unpredictable environment. While sector leader Moderna (MRNA) surged 7.05% today, highlighting the divergence in biotech sentiment, SLS remains in a precarious position. Watch for a breakdown below $11.00 or any official response from management regarding the REGAL trial data release as the primary signals to reassess.